The senior management consists of the Chief Executive Officer, Chief Scientific Officer, Chief Operating Officer, Chief Financial Officer, Chief Medical Officer, Chief Commercial Officer, Head of Corporate Communications and Head of Human Resources.

Monica Shaw, CEO Oncopeptides AB

Monica Shaw, MD

Chief Executive Officer

Monica Shaw was appointed Chief Executive Officer in 2023.


Monica is a Medical Doctor with breadth of leadership experience. She was Executive Vice President, Head Europe/Canada and Global Marketing Psoriasis, LEO Pharma 2020-2022. She was VP and Head of Asia Pacific Region for GSK/ViiV Healthcare Singapore 2018-2020, General Manager GSK Panama, 2016-2018 and VP Global Franchise Head for Specialty, GSK 2014-2016. Prior to that she held managerial roles in Medical Affairs and Clinical Development for several pharmaceutical companies, and worked as a Medical Doctor.


Monica took a MBBS MA, Medical Degree at Oxford University in 2002, and became a Member of the Royal College of Physicians in UK in 2005.


Born: 1978
Holdings in Oncopeptides: -
Other current positions: Non-executive Board Director, AC Immune

Jakob Lindberg

Jakob Lindberg, Med Lic

Chief Scientific Officer (CSO)

Jakob Lindberg was appointed CSO in 2023.


In addition to being CSO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, a part of Investor AB.


Jakob Lindberg was the CEO of Oncopeptides from the restart of the company in 2011, until June 2020, as well as from November 2021 until January 2023. During July 2020 until November 2021 he was the CSO of Oncopeptides. His previous roles include being an analyst at Merrill Lynch & Co and a consultant at McKinsey & Co. Jakob was co-founder of Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.


Jakob has studied medicine at the Karolinska Institute. He gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from the Stockholm University.


Born: 1972
Holdings in Oncopeptides: 868,331 shares (853,031 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB), 175,663 share awards* and 605,081 options*.
Other current positions: CEO of Oncopeptides, Inc, director of Oncopeptides Incentive AB, director of Affibody Medical AB and Lindberg Life-Science AB. CEO of Lindberg Life-Science AB.

Eva Nordström

Eva Nordström, MSc Pharm

Chief Operating Officer (COO) and Deputy Managing Director

Eva Nordström was appointed as Head of Clinical Development in 2012, Chief Operating Officer 2020 and Deputy Managing Director 2021. Eva is responsible for strategic and operational deliveries in Biostatistics, CMC, Clinical Operations, Data Management, Global Drug Supply and Preclinical Operations.


Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.


Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.


Born: 1970
Holdings in Oncopeptides: 120,200 shares, 87,832 share awards* and 284,113 options*.
Other current positions: Board member of Oxcia AB, Alternate Director of Utilica AB.

Holger Lembrér, CFO

Holger Lembrér, MSc

Chief Financial Officer (CFO)

Holger was appointed CFO in 2023, and is responsible for Finance, Legal, IT & Administration.


Prior to joining Oncopeptides Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, Financial Controller, and Controller. He has also been a Senior Auditor at Ernst & Young.


Holger holds a Master of Science degree in Business and Economics, from the University of Uppsala, Sweden.


Born: 1984
Holdings in Oncopeptides: -
Other current positions: -

Klaas Bakker

Klaas Bakker, MD, PhD

Head of R&D and Chief Medical Officer (CMO)

Klaas Bakker was appointed as Chief Medical Officer in 2019 and Head of Research and Development in 2022. In this role he is accountable for the Research and Clinical Development Strategy, Regulatory Affairs,Pharmacovigilance and Medical Affairs.


Klaas has previously held various roles at AstraZeneca within their global Oncology Business Unit, including Vice President Medical Affairs of the Global TAGRISSO-TDR Franchise in Oncology, where he was responsible for several drugs, including AstraZeneca’s drug osimertinib.


Klaas holds an MD and is a board-certified neurosurgeon from the university of Groningen, the Netherlands, where he was clinically active until 2015. In addition, he holds a PhD in Immuno-Hematology and has authored over 50 publications in international peer-reviewed journals.


Born: 1982
Holdings in Oncopeptides: 100,000 shares, 29,277 share awards* and 179,384 options*.
Other current positions: Director of Trust office foundation (STAK) AI-InfraSolutions

Rolf Gulliksen, Global Head of Corporate Communications

Rolf Gulliksen

Global Head of Corporate Communications

Rolf Gulliksen was appointed as Global Head of Corporate Communications in 2020. 


Rolf has an extensive background in strategic communication for the life science industry and consultancy. Previous positions include Head of Corporate Communications at Hansa Biopharma, SVP Corporate Communications Biovitrum, Corporate Affairs Director Pfizer, VP Public Affairs and Communications Pharmacia in EMEA, and External Affairs Manager at MSD. He has also headed the life science business at leading communication agencies; Hallvarsson and Halvarsson Group, Springtime, InVivo, and Edelman Worldwide in Europe


Rolf has studied chemistry, biology, physics, geology, pedagogy and methodology at Uppsala University


Born: 1959
Holdings in Oncopeptides: 50,000 share awards* and 5,499 options*.
Other current positions: CEO and Senior Advisor, Gulliksen Strategic Relations AB

Sara Svärdgren - Head of Human Resources

Sara Svärdgren

Head of Human Resources

Sara joined Oncopeptides in May 2018 as Head of Human Resources. Since May 2022, she is a member of the company’s leadership team.


Sara has a broad experience of HR and has held managerial positions in HR during the past 10 years. Before joining Oncopeptides, she worked in the financial industry at Neonet Securities AB.


Sara has studied the Human Resources program with a major in psychology at Örebro University and Stockholm University.


Born: 1979
Holdings in Oncopeptides: 85 shares, 21,550 share awards* and 9,498 options*.

Sofia Heigis, Chief Commercial Officer and  Managing Director Germany

Sofia Heigis, MSc

Chief Commercial Officer, CCO, and Managing Director Germany

Sofia joined Oncopeptides in August 2020 as Senior Vice President and Global Head Medical Affairs. She was appointed Chief Commercial Officer and Managing Director Germany in 2022. Sofia was engaged in the preparedness and launch of Pepaxto in the US, and has led the preparations of the commercialization of Pepaxti in Europe. She has been a member of the Leadership Team since November 2021.


Sofia brings broad experience from leading international roles in Medical Affairs, Medical and Regulatory Affairs, as well as several Marketing and Sales roles at Astra Zeneca, and has been engaged in both global and local product launches.


Sofia holds a Master of Pharmacology from the University of Gothenburg, including a Master Thesis in Pharmacology from Bond University. She has an Executive Master in Strategy, and is a member of the business network for female leaders, Ruter Dam.


Born: 1980
Holdings in Oncopeptides: 20,104 shares, 123,531 share awards* and 96,532 options*.
Other current positions: -

* The options and share awards entitles to one share per option in accordance with existing terms.

For more information and terms please read under Corporate Governance – Remuneration.


Holdings in Oncopeptides AB (publ) as of October 10, 2022.